Biopharmaceutical firm Zalicus has started a Phase Ib clinical trial of Z944, a novel oral T-type calcium channel blocker, for the treatment of neuropathic pain.

The company expects to release the results from the laser-evoked potentials (LEP) study in the fourth quarter of 2013.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study is designed to offer both objective and subjective data on a drug’s ability to modulate pain signalling.

In addition to subject-reported pain scores, vertex-Electroencephalography (EEG) is used to quantify electrical voltage fluctuations induced by laser thermal stimulation in this LEP clinical model study.

The LEP model has been used as an effective tool in benchmarking the efficacy of Z944 against other therapies in several pain drug studies.

See Also:
"T-type calcium channels are known to be widely implicated in the frequency and intensity of pain signals and the results of this study will further inform Zalicus’sdevelopment plans for Z944 in a variety of potential indications as we work to optimise a modified release formulation of Z944 for future clinical trials."

Zalicus MD, president and CEO Mark Corrigan said measuring LEP is an experimental clinical model that provides both subjective and objective measures to assess the potential of Z944 to modulate pain signalling.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"T-type calcium channels are known to be widely implicated in the frequency and intensity of pain signals and the results of this study will further inform Zalicus’sdevelopment plans for Z944 in a variety of potential indications as we work to optimise a modified release formulation of Z944 for future clinical trials," Corrigan said.

The T-type calcium channels have been recognised as major targets for therapeutic intervention in a range of cell functions and have been implicated in pain signalling.

And Z944, a state-dependent, selective T-type calcium channel blocker, has showed preclinical efficacy in multiple inflammatory pain models

The company has already completed Phase I single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944.